Centene Corporation (CNC)

In the past six months, Centene's stock price has experienced significant fluctuations. The stock closed at $38.46 on February 6, 2026, a 3.66% decrease for the day. Over the past year, the stock has ranged between $25.08 and $66.03. Centene reported a smaller-than-expected adjusted diluted loss per share of $1.19 in its Q4 2025 earnings report, with revenue surpassing expectations at $49.73 billion. Ongoing Medicaid eligibility redeterminations and emerging Marketplace subsidy eligibility headwinds are expected to pressure results. Centene's Q4 2025 medical loss ratio was 94.3%, higher than the previous year. Analyst sentiment is mixed regarding the recovery of Medicaid and Exchange programs.

Centene's products and services exhibit demand seasonality, with the majority of its 2026 adjusted EPS expected in Q1, stepping down in Q2, reaching around break-even in Q3, and resulting in a loss in Q4. This is primarily due to the design of Marketplace and Medicare Prescription Drug Plan (PDP) benefits, which tend to produce lower Health Benefits Ratios (HBRs) early in the year and higher HBRs later in the year.

Centene Corporation is an American for-profit healthcare company operating as a managed care provider, focusing on government-sponsored programs like Medicaid and Medicare, and commercial programs. Its major products and services are organized across four segments: Medicaid, Medicare, Commercial, and Other. Centene is the largest Medicaid managed care organization in the U.S., serving approximately 13 million members as of Q1 2025. The Medicaid segment offers programs including TANF, Medicaid expansion, ABD programs, CHIP, long-term services and supports, foster care, and Medicare-Medicaid plans. The Medicare segment provides Special Needs Plans, Medicare Supplement plans, and Prescription Drug Plans (Part D). The Commercial segment offers health insurance marketplace products. The Other segment encompasses various healthcare-related operations and services.

Centene Corporation operates across all 50 U.S. states, serving over 28 million managed care members nationwide as of 2024, emphasizing a localized approach to healthcare delivery. Centene divested its UK subsidiary, Circle Health, in August 2023.

Centene's mission is centered on transforming community health, particularly for underserved populations. The reported net loss of $1.1 billion in Q4 2025 and rising No Surprises Act billing disputes could raise concerns. Medicaid redeterminations can lead to members losing coverage, impacting public perception. Centene is integrating AI into its operations to improve efficiency and is investing in addressing social determinants of health.

Approximately 49.00% of Centene Corporation's stock is owned by institutional investors, 0.61% by insiders, and 50.39% by public companies and individual investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Recent insider trading activity shows some selling by directors in late 2025, including Kenneth Burdick.